-
DR10627, a Novel Dual Glucagon‑like Peptide‑1 and Gastric Inhibitory Polypeptide Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes Mellitus
05 Apr 2024 16:19 GMT
… are also safe medications in treatment of diabetics with … FDA for managing obesity, without concurrent diabetes. The SCALE trials … increasing, for instance, taspoglutide, which contains Aib ( … Corporation, Zhejiang Heze Pharmaceutical Technology Co., Ltd …
-
Roche to Accelerate Development of Obesity Assets from $2.7B Carmot Buy
26 Jul 2024 13:58 GMT
… company take its weight-loss treatments “much faster to the … 7 billion to acquire California biotech Carmot Therapeutics and its … Phase III GLP-1 analog taspoglutide in 2011, citing safety … .
Unlike currently available obesity medications, CT-388 and CT- …
-
Roche Jumps into Lucrative Weight-Loss Space with $2.7B Carmot Buy
04 Dec 2023 15:05 GMT
… combination with other weight-loss treatments for patients with and … Garraway, Roche’s chief medical officer and head of global … small but courageous club of biotechs that have sought to … 1 analog taspoglutide, which entered into Phase III clinical trials in …
-
Optimizing Pharmacological and Immunological Properties of Therapeutic Proteins Through PEGylation: Investigating Key Parameters and Their Impact
07 Nov 2024 09:03 GMT
… scale production of pharmaceutical-grade proteins and … taspoglutide, amylin, and pramlintide.52–54
Anti-Drug Immunogenicity … to conventional treatment: two randomized controlled trials. JAMA. … 47;www.fda.gov/files/vaccines,%20blood%20%26%20biologics…